Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the Formula (I-1):



I-1

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

Z is -C(O)~~-, -C(O)O-, or -C(-Q-R_{1-3})$_2$-~~;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl,

-N(CH_3)(OCH_3), and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO_2-R_{1-4},

-NH-C(O)-R_{1-4},

-NH-C(O)-NH_2,

-NH-C(O)-NH-R_{1-4}, and

-N_3;

~~with the proviso that if Z is -C(O)-, then R_{1-1} may also be -N(CH_3)(OCH_3);~~

~~with the further proviso that if Z is -C(O)O-, then R_{1-1} is not hydrogen;~~

~~with the further proviso that if Z is -C(O)O-, then X does not include -O- groups;~~

~~Q is O or S;~~

~~R_{1-3} is selected from the group consisting of:~~

~~alkyl,~~

~~aryl,~~

~~alkylene-aryl,~~

~~heteroaryl,~~

~~alkylene-heteroaryl, and~~

~~alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:~~

~~halogen,~~

~~cyano,~~

~~nitro,~~

~~alkoxy,~~

~~dialkylamino,~~

~~alkylthio,~~

~~haloalkyl,~~

~~haloalkoxy,~~

~~alkyl,~~

~~-NH-SO_2-R_{1-4};~~

~~-NH-C(O)-R_{1-4};~~

~~-NH-C(O)-NH_2;~~

~~-NH-C(O)-NH-R_{1-4}; and~~

~~-N_3;~~

~~or the R_{1-3} groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;~~

R_{1-4} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

-N_3; and

R_2 is selected from the group consisting of:

-R_4,

-X'-R_4,

-X'-Y'-R_4, and

-X'-R_5;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally

interrupted or terminated with arylene, or heteroarylene, and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:

$-S(O)_{0-2}-$,

$-S(O)_2-N(R_8)-$,

$-C(R_6)-$,

$-C(R_6)-O-$,

$-O-C(R_6)-$,

$-O-C(O)-O-$,

$-N(R_8)-Q'-$,

$-C(R_6)-N(R_8)-$,

$-O-C(R_6)-N(R_8)-$,

$-C(R_6)-N(OR_9)-$,



,



, and



;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;

R_5 is selected from the group consisting of:

 and ;

R_6 is selected from the group consisting of =O and =S;

R_7 is a C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R_9 is selected from the group consisting of hydrogen and alkyl;

R_{10} is C_{3-8} alkylene;

A is selected from the group consisting of -O-, -C(O)-, $-S(O)_{0-2}$-, $-CH_2$-, and $-N(R_4)$-;

Q' is selected from the group consisting of a bond, $-C(R_6)$-, $-C(R_6)-C(R_6)$-, $-S(O)_2$-, and $-S(O)_2-N(R_8)$-;

V is selected from the group consisting of $-C(R_6)$-, $-O-C(R_6)$-, and $-S(O)_2$-;

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7;

R_A and R_B are each independently selected from the group consisting of:

hydrogen,

halogen,

alkyl,

alkenyl,

alkoxy,

alkylthio, and

$-N(R_9)_2$;

or R_A and R_B taken together form either a fused aryl ring that is unsubstituted or substituted by one or more R groups, or a fused 5 to 7 membered saturated ring that is unsubstituted or substituted by one or more R_a groups;

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

-$N(R_9)_2$; and

R_a is selected from the group consisting of:

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

-$N(R_9)_2$;

or a pharmaceutically acceptable salt thereof.

2. (currently amended) A compound of the Formula (I-2):



I-2

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

Z is -C(O)-, ~~-C(O)O-, or -C(-Q-R_{1-3})$_2$-~~;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl,

-$N(CH_3)(OCH_3)$, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO_2-R_{1-4},

-NH-C(O)-R_{1-4},

-NH-C(O)-NH_2,

-NH-C(O)-NH-R_{1-4}, and

-N_3;

~~with the proviso that if Z is -C(O)-, then R_{1-4} may also be -N(CH_3)(OCH_3);~~

~~with the further proviso that if Z is -C(O)O-, then R_{1-4} is not hydrogen;~~

~~with the further proviso that if Z is -C(O)O-, then X does not include -O- groups;~~

~~Q is O or S;~~

~~R_{1-3} is selected from the group consisting of:~~

~~alkyl,~~

~~aryl,~~

~~alkylene-aryl,~~

~~heteroaryl,~~

~~alkylene-heteroaryl, and~~

~~alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:~~

~~halogen,~~

~~cyano,~~

~~nitro,~~

~~alkoxy,~~

~~dialkylamino,~~

~~alkylthio,~~

~~haloalkyl,~~

~~haloalkoxy,~~

~~alkyl,~~

~~$-NH-SO_2-R_{1-4}$;~~

~~$-NH-C(O)-R_{1-4}$;~~

~~$-NH-C(O)-NH_2$;~~

~~$-NH-C(O)-NH-R_{1-4}$; and~~

~~$-N_3$;~~

~~or the R_{1-3} groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;~~

R_{1-4} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

$-N_3$; and

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

$-N(R_9)_2$;

R_2 is selected from the group consisting of:

$-R_4$,

$-X'-R_4$,

$-X'-Y'-R_4$, and

$-X'-R_5$;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene or heteroarylene, and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:

$-S(O)_{0-2}-$,

$-S(O)_2-N(R_8)-$,

$-C(R_6)-$,

$-C(R_6)-O-$,

$-O-C(R_6)-$,

$-O-C(O)-O-$,

$-N(R_8)-Q'-$,

$-C(R_6)-N(R_8)-$,

$-O-C(R_6)-N(R_8)-$,

$-C(R_6)-N(OR_9)-$,



,


, and


;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;

R_5 is selected from the group consisting of:


;

R_6 is selected from the group consisting of =O and =S;

R_7 is a C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R_9 is selected from the group consisting of hydrogen and alkyl;

R_{10} is C_{3-8} alkylene;

A is selected from the group consisting of -O-, -C(O)-, $-S(O)_{0-2}-$, $-CH_2-$, and $-N(R_4)-$;

Q' is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, and $-S(O)_2-N(R_8)-$;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, and $-S(O)_2-$; and

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7;

or a pharmaceutically acceptable salt thereof.

3. (currently amended) A compound of the Formula (I-3):



I-3

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

Z is -C(O)-, -C(O)O-, or -C(-Q-R_{1-3})$_2$-;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO_2-R_{1-4},

-NH-C(O)-R_{1-4},

-NH-C(O)-NH_2,

-NH-C(O)-NH-R_{1-4}, and

-N_3;

with the proviso that if Z is -C(O)-, then R_{1-1} may also be -$N(CH_3)(OCH_3)$;

with the further proviso that if Z is -C(O)O-, then R_{1-1} is not hydrogen;

with the further proviso that if Z is -C(O)O-, then X does not include -O- groups;

Q is O or S;

R_{1-3} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO_2-R_{1-4},

-NH-C(O)-R_{1-4},

-NH-C(O)-NH_2,

-NH-C(O)-NH-R_{1-4}, and

-N_3;

or the R_{1-3} groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;

R_{1-4} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

$-N_3$; and

R_2 is selected from the group consisting of:

$-R_4$,

$-X'-R_4$,

$-X'-Y'-R_4$, and

$-X'-R_5$;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene or heteroarylene, and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:

$-S(O)_{0-2}-$,

$-S(O)_2-N(R_8)-$,

$-C(R_6)-$,

$-C(R_6)-O-$,

$-O-C(R_6)-$,

$-O-C(O)-O-$,

$-N(R_8)-Q'-$,

$-C(R_6)-N(R_8)-$,

$-O-C(R_6)-N(R_8)-$,

$-C(R_6)-N(OR_9)-$,



,



, and



;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;

R_5 is selected from the group consisting of:



and



;

R_6 is selected from the group consisting of =O and =S;

R_7 is a C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R_9 is selected from the group consisting of hydrogen and alkyl;

R_{10} is C_{3-8} alkylene;

A is selected from the group consisting of -O-, -C(O)-, $-S(O)_{0-2}-$, $-CH_2-$, and $-N(R_4)-$;

Q' is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, and $-S(O)_2-N(R_8)-$;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, and

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7; and

$R_{A'}$ and $R_{B'}$ are each independently selected from the group consisting of:

hydrogen,

halogen,

alkyl,

alkenyl,

alkoxy,

alkylthio, and

$-N(R_9)_2$;

or a pharmaceutically acceptable salt thereof.

4. (canceled)

5. (original) A compound of the Formula (Ia):



Ia

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl,

$-N(CH_3)(OCH_3)$, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

$-NH-SO_2-R_{1-4}$,

$-NH-C(O)-R_{1-4}$,

$-NH-C(O)-NH_2$,

$-NH-C(O)-NH-R_{1-4}$, and

$-N_3$;

R_{1-4} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

$-N_3$;

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

$-N(R_9)_2$;

R_2 is selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

heteroaryl,

heterocyclyl,

alkylene-Y-alkyl,

alkylene-Y-alkenyl,

alkylene-Y-aryl, and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

hydroxy,

halogen,

$-N(R_3)_2$,

$-C(O)-C_{1-10}$alkyl,

$-C(O)-O-C_{1-10}$alkyl,

$-N(R_3)-C(O)-C_{1-10}$alkyl,

$-N_3$,

aryl,

heteroaryl,

heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

wherein:

Y is –O– or $–S(O)_{0-2}$-;

R_3 is selected from the group consisting of:

hydrogen,

C_{1-10}alkyl, and

C_{2-10}alkenyl; and

R_9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

6. (canceled)

7. (original) A compound of the Formula (Id):



Id

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

$-NH-SO_2-R_{1-4}$,

$-NH-C(O)-R_{1-4}$,

-NH-C(O)-NH_2,

-NH-C(O)-NH-R_{1-4}, and

-N_3;

Q is O or S;

R_{1-3} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO_2-R_{1-4},

-NH-C(O)-R_{1-4},

-NH-C(O)-NH_2,

-NH-C(O)-NH-R_{1-4}, and

-N_3;

or the R_{1-3} groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;

R_{1-4} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

$-N_3$;

R is selected from the group consisting of:

fluoro,

alkyl,

alkoxy,

haloalkyl, and

$-N(R_9)_2$;

R_2 is selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

heteroaryl,

heterocyclyl,

alkylene-Y-alkyl,

alkylene-Y-alkenyl,

alkylene-Y-aryl, and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

hydroxy,

halogen,

$-N(R_3)_2$,

$-C(O)-C_{1-10}$alkyl,

$-C(O)-O-C_{1-10}$alkyl,

$-N(R_3)-C(O)-C_{1-10}$alkyl,

$-N_3$,

aryl,

heteroaryl,

heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

wherein:

Y is –O– or $–S(O)_{0-2}$-; and

R_3 is selected from the group consisting of:

hydrogen,

C_{1-10}alkyl, and

C_{2-10}alkenyl; and

R_9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

8. (original) A compound of the Formula (Ie):



Ie

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

R is selected from the group consisting of:

fluoro,

alkyl,

alkoxy,

haloalkyl, and

$-N(R_9)_2$;

R_2 is selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

heteroaryl,

heterocyclyl,

alkylene-Y-alkyl,

alkylene-Y-alkenyl,

alkylene-Y-aryl, and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

hydroxy,

halogen,

$-N(R_3)_2$,

$-C(O)-C_{1-10}$alkyl,

$-C(O)-O-C_{1-10}$alkyl,

$-N(R_3)-C(O)-C_{1-10}$alkyl,

$-N_3$,

aryl,

heteroaryl,

heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

wherein:

Y is –O– or –$S(O)_{0-2}$-; and

R_3 is selected from the group consisting of:

hydrogen,

C_{1-10}alkyl, and

C_{2-10}alkenyl; and

R_9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

9. (original) The compound or salt of claim 3 wherein $R_{A'}$ and $R_{B'}$ are independently selected from the group consisting of hydrogen and alkyl.

10. (canceled)

11. (currently amended) The compound or salt of ~~any one of~~ claim~~s~~ 2 ~~or 4 through 8~~ wherein n is 0.

12. (currently amended) The compound or salt of ~~any one of~~ claim~~s 1~~ 3~~through 4, 9, or 10, or claim 11 as dependent on either of claims 2 or 4,~~ wherein Z is -C(O)-.

13-14 (canceled)

15. (currently amended) The compound or salt of claim ~~14~~ 7 wherein R_{1-3} is alkyl, or the R_{1-3} groups join to form a 5-membered ring.

16. (canceled)

17. (currently amended) The compound or salt of ~~any one of~~ claims ~~1 through 4,~~ 7~~, 9, or 10, or claim 11 as dependent on any one of claims 2, 4, or 7, or claims 14 through 16,~~ wherein each Q is -O-.

18. (currently amended) The compound or salt of ~~any one of~~ claims 1 ~~through 5, 9, or 10, or claim 11 as dependent on anyone of claims 2, 4, or 5, or claim 12,~~ wherein R_{1-1} is selected from the group consisting of aryl, alkyl, and $-N(CH_3)OCH_3$.

19. (currently amended) The compound or salt of ~~any one of~~ claims ~~1 through 5,~~ 7~~, 9, 10, or claim 11 as dependent on any one of claims 2, 4, 5, or 7, or claim 12, or claims 14 through 17,~~ wherein R_{1-1} is selected from the group consisting of alkyl, aryl, and hydrogen.

20. (currently amended) The compound or salt of ~~any one of~~ claims 1 ~~through 5, 7 through 10, or claim 11 as dependent on anyone of claims 2, 4, 5, 7, or 8, or claim 12, or claims 14 through 19,~~ wherein X is a C_{1-6} alkylene or $-(CH_2)_{2-4}-O-(CH_2)_{1-3}-$.

21. (original) The compound or salt of claim 20 wherein X is selected from the group consisting of $-(CH_2)_{1-6}-$, $-CH_2-C(CH_3)_2-$, $-(CH_2)_2-O-CH_2-$, $-(CH_2)_3-O-CH_2-$, and $-CH_2-C(CH_3)_2-CH_2-$.

22. (currently amended) The compound or salt of ~~any one of~~ claims 1 ~~through 7, 9, or 10; or claim 11 as dependent on any one of claims 2, or 4 through 7; or claims 12 through 19; or claim 20 as dependent on any one of claims 1 through 5, 7, 9, 10, or claim 11 as dependent on any one of claims 2, 4, 5, or 7, or claims 14 through 19; or claim 21 as dependent on any one of claims 1 through 5, 7, 9, 10, or claim 11 as dependent on any one of claims 2, 4, 5, or 7, or claims 14 through 19,~~ wherein R_{1-1} is selected from the group consisting of alkyl and aryl.

23. (original) The compound or salt of claim 22 wherein R_{1-1} is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

24. (canceled)

25. (currently amended) The compound or salt of ~~any one of~~ claim~~s~~ 1 ~~through 24~~ wherein R_2 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.

26. (original) The compound or salt of claim 25 wherein R_2 is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

27-28 (canceled)

29. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of ~~any one of~~ claim~~s~~ 1 ~~through 28~~ in combination with a pharmaceutically acceptable carrier.

30. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of ~~any one of~~ claim~~s~~ 1 ~~through 28~~ to the animal.

31. (currently amended) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of ~~any one of~~ claim~~s~~ 1 ~~through 28~~ to the animal.

32. (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of ~~any one of~~ claim~~s~~ 1 ~~through 28~~ to the animal.

33-35 (canceled)

36. (new) The compound or salt of claim 2 wherein X is a $C_{1\text{-}6}$ alkylene or

$-(CH_2)_{2-4}-O-(CH_2)_{1-3}-$.

37. (new) The compound or salt of claim 36 wherein X is selected from the group consisting of $-(CH_2)_{1-6}-$, $-CH_2-C(CH_3)_2-$, $-(CH_2)_2-O-CH_2-$, $-(CH_2)_3-O-CH_2-$, and $-CH_2-C(CH_3)_2-CH_2-$.

38. (new) The compound or salt of claim 2 wherein R_{1-1} is selected from the group consisting of alkyl and aryl.

39. (new) The compound or salt of claim 38 wherein R_{1-1} is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

40. (new) The compound or salt of claim 2 wherein R_2 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.

41. (new) The compound or salt of claim 40 wherein R_2 is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

42. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

43. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

44. (new) The compound or salt of claim 3 wherein X is a C_{1-6} alkylene or $-(CH_2)_{2-4}-O-(CH_2)_{1-3}-$.

45. (new) The compound or salt of claim 3 wherein R_{1-1} is selected from the group consisting of alkyl and aryl.

46. (new) The compound or salt of claim 3 wherein R_2 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.

47. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 3 in combination with a pharmaceutically acceptable carrier.

48. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 3 to the animal.

49. (new) The compound or salt of claim 7 wherein n is 0.

50. (new) The compound or salt of claim 7 wherein X is a C_{1-6} alkylene or $-(CH_2)_{2-4}-O-(CH_2)_{1-3}-$.

51. (new) The compound or salt of claim 7 wherein R_2 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.

52. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 7 in combination with a pharmaceutically acceptable carrier.

53. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 7 to the animal.

54. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 8 in combination with a pharmaceutically acceptable carrier.

55. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 8 to the animal.